EDO-B278

EDO-B278 is an antibody-drug conjugate (ADC) in pre-clinical development for the treatment of various solid tumors, including prostate, colorectal, non-small cell lung (NSCLC), breast, melanoma, pancreatic, and gastric cancers. Developed by Mundipharma EDO GmbH with research directed for Purdue Pharma, the agent targets human tissue factor (TF), which is frequently overexpressed in malignant tissues. EDO-B278 is designed to bind with high affinity to tumor cells while avoiding the inhibition of tissue factor-mediated blood coagulation, a feature intended to minimize potential bleeding side effects. As an ADC, it utilizes a monoclonal antibody to deliver a cytotoxic payload specifically to TF-expressing cancer cells.